Fidaxomicin

Fidaxomicin is a macrocyclic antibiotic used to treat Clostridioides difficile infection (CDI). It is a narrow-spectrum oral agent designed to act primarily in the gut, with minimal systemic absorption.

Mechanism of action and spectrum: Fidaxomicin inhibits the sigma subunit of bacterial RNA polymerase, blocking initiation of RNA synthesis in susceptible organisms. In vitro and clinical data show it is highly active against C. difficile and has limited activity against most other gut bacteria, helping preserve much of the normal microbiota and potentially reducing recurrence.

Pharmacology and pharmacokinetics: After oral administration, fidaxomicin and its metabolites achieve very high concentrations in the colon with only minimal systemic exposure. It is not appreciably metabolized in the liver and is primarily excreted in the feces. This pharmacokinetic profile supports its use as a gut-directed therapy with a relatively favorable safety profile.

Clinical use and dosing: In the United States, fidaxomicin (brand name Dificid) is approved for the treatment of CDI in adults. The standard dosing is 200 mg taken orally twice daily for 10 days. Compared with vancomycin, fidaxomicin has been associated in cost-effectiveness analyses with lower rates of CDI recurrence in certain patient groups, and guidelines often cite its role as a first-line option for non-severe CDI or as an alternative for initial CDI to reduce recurrence, depending on specific recommendations. It is not indicated for fulminant CDI in most guidelines.

Safety and resistance: Adverse events are generally mild and include nausea, abdominal pain, and vomiting. Because systemic exposure is low, systemic drug interactions are limited, though clinicians monitor for interactions as with any antimicrobial. Resistance remains uncommon, but rare cases of reduced susceptibility have been reported in vitro.